Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Cann Group ( (AU:CAN) ) is now available.
Cann Group Limited announced the results of its General Meeting, where all resolutions were passed following a poll vote. The meeting included significant decisions such as the election of a director and the ratification of share and option issuances, which are expected to impact the company’s strategic direction and stakeholder interests positively.
More about Cann Group
Cann Group Limited is an Australian company focused on enhancing patients’ lives through the development, production, and supply of innovative cannabis medicines. The company operates research facilities and a large-scale cultivation and GMP manufacturing facility in Victoria, supplying a range of dried flower, oil products, active pharmaceutical ingredients, and extracts to both Australian and international markets. Cann Group also owns Satipharm, known for its patent-protected capsule technology.
Average Trading Volume: 1,822,776
Technical Sentiment Signal: Sell
Current Market Cap: A$9.02M
For detailed information about CAN stock, go to TipRanks’ Stock Analysis page.